2 results match your criteria: "Department of Cardiovascular Disease Mayo Clinic Rochester MN USA.[Affiliation]"
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy.
J Am Heart Assoc
July 2024
Cardiovascular Division, Brigham and Women's Hospital Harvard Medical School Boston MA USA.
Article Synopsis
- Researchers studied serum levels of 4123 proteins in 1117 patients with heart failure with preserved ejection fraction (HFpEF) to identify prognostic markers linked to clinical outcomes.
- A total of 288 proteins were found to be significantly associated with heart failure hospitalization and cardiovascular death, with specific proteins like B2M and TIMP1 showing strong correlations.
- The study concluded that the protein markers for HFpEF are similar to those for heart failure with reduced ejection fraction, implying that the derived proteomic risk scores do not offer improved predictive power for HFpEF patients.
Background Patient-reported outcome measures have been shown to have important prognostic value after various cardiac interventions. We assessed the association between the change in Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) score after transcatheter aortic valve replacement and mortality. Methods and Results We included patients who underwent transcatheter aortic valve replacement at Mayo Clinic between February 2012 to June 2022 and who completed a KCCQ-12 before and 30 to 45 days after the procedure.
View Article and Find Full Text PDF